Home Blog Page 21

PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Other Events

PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Other Events
Item 8.01 Other Events.

On June 18, 2021, PharmaCyte Biotech, Inc. (“PharmaCyte”) announced that its Annual Meeting of Stockholders, held virtually on Wednesday, June 16, 2021, has been adjourned until Wednesday, June 30, 2021, at 11:00 A.M. PDT in order to allow additional time for stockholders to vote on Proposal No. 2, the proposal to increase the authorized number of shares of capital stock. When the annual meeting is reconvened on June 30, 2021, it will continue to be held virtually at https://www.virtualshareholdermeeting.com/PMCB2021. A copy of the press release is attached as Exhibit 99.1 herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 


PharmaCyte Biotech, Inc. Exhibit
EX-99.1 2 pharmacyte_8k-ex9901.htm PRESS RELEASE: PHARMACYTE BIOTECH ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF SHAREHOLDERS,…
To view the full exhibit click here

About PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB)

PharmaCyte Biotech, Inc., formerly Nuvilex, Inc., is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Company’s Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. The Company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type I diabetes and insulin-dependent Type II diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using its Cell-in-a-Box technology.

Story continues below

ACASTI PHARMA INC. (NASDAQ:ACST) Files An 8-K Results of Operations and Financial Condition

ACASTI PHARMA INC. (NASDAQ:ACST) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued by Acasti Pharma Inc. on June 22, 2021

Acasti Pharma Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1 Acasti Pharma Provides Fiscal 2021 Year-End Business UpdateUpdate on Acquisition of Grace Therapeutics and Strategic Plans for CaPre LAVAL,…
To view the full exhibit click here

About ACASTI PHARMA INC. (NASDAQ:ACST)

Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s prescription drug candidate is CaPre, which is being developed for the treatment of severe hypertriglyceridemia and eventually mild to moderate hypertriglyceridemia. The Company’s ONEMIA has a natural health product status in Canada, and it is commercialized as a medical food in the United States. Onemia is a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content than CaPre.

Story continues below

Digipath, Inc. (OTCMKTS:DIGP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Digipath, Inc. (OTCMKTS:DIGP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 18, 2021, Todd Peterson resigned from his positions as Chief Financial Officer, Secretary and Treasurer of Digipath, Inc. (the “Company”), effective June 18, 2021.

Story continues below

Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Other Events

Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Other Events
Item 8.01 Other Events.


About Tyme Technologies, Inc. (OTCMKTS:TYMI)

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.

Story continues below

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events
Item 8.01

On June 18, 2021, Second Sight Medical Products, Inc. (“the Company”) posted an updated corporate deck which can be found on the Company’s website at https://investors.secondsight.com/events/event-details/eyes-corporate-investor-deck-june-2021.

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Story continues below

DAVIDsTEA Inc. (NASDAQ:DTEA) Files An 8-K Bankruptcy or Receivership

DAVIDsTEA Inc. (NASDAQ:DTEA) Files An 8-K Bankruptcy or Receivership
Item 1.03 Bankruptcy or Receivership.

As previously disclosed, on July 8, 2020, DAVIDsTEA Inc. (the “Company”), a corporation incorporated under the Canada Business Corporations Act, and its wholly-owned subsidiary, DAVIDsTEA (USA), Inc. (the “Subsidiary” and together with the Company, the “Debtors”) commenced proceedings (the “Canadian Proceedings”) under the Companies’ Creditors Arrangement Act (Canada) (the “CCAA”) with the Québec Superior Court (the “Canadian Court”). On July 8, 2020, the Canadian Court issued an order, which, among other things, appointed PricewaterhouseCoopers Inc., a licensed insolvency trustee, as monitor (the “Monitor”), in accordance with the provisions of the CCAA.

As previously disclosed, on July 8, 2020, the Monitor also filed petitions under Chapter 15 of the United States Bankruptcy Code for recognition of the Canadian Proceedings and related relief. After issuing an order granting provisional relief, on August 4, 2020, the United States Bankruptcy Court for the District of Delaware (the “U.S. Court”) issued an order recognizing the Canadian Proceedings as the foreign main proceedings on a final basis and providing certain related relief.

On June 16, 2021, the Canadian Court entered an order (the “Sanction Order”) sanctioning, approving and enforcing the Plan of Compromise and Arrangement dated May 4, 2021 (as amended on May 6, 2021, the “Plan”) which the Debtors had filed under the CCAA. On June 17, 2021, the U.S. Court entered an order (the “U.S. Order”) giving full force and effect in the United States to the Sanction Order.

The following is a summary of the material terms of the Plan. This summary highlights only certain substantive provisions of the Plan and is not intended to be a complete description of the Plan. This summary is qualified in its entirety by reference to the full text of the Plan, the Sanction Order and the U.S. Order, which are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and incorporated by reference herein. Capitalized terms used but not defined in this Current Report on Form 8-K have the meanings set forth in the Plan.

Plan of Compromise and Arrangement

The Plan provides for an aggregate distribution of approximately CAN$18 million, comprised of three funds: (i) the Canadian Convenience Class Fund, (ii) the DT Fund and (iii) the DT USA Fund, to be distributed to the classes of unsecured creditors as detailed below. The Plan divides unsecured creditors into those having claims against the Company (the “Unsecured Creditors of DT”) and those having claims against the Subsidiary (the “Unsecured Creditors of DT USA”).

Distributions to Creditors of the Company

For purposes of receiving distributions under the Plan, Unsecured Creditors of DT who have a Proven Claim of up to CAN$1,800 will be deemed to form part of a convenience class (the “Canadian Convenience Class”). All Unsecured Creditors of DT who have a Proven Claim in excess of CAN$1,800 have the option to elect to form part of the Canadian Convenience Class. The distribution of the Canadian Convenience Class Fund and the DT Fund to creditors of the Company under the Plan is summarized as follows:

 

DAVIDsTEA Inc. Exhibit

To view the full exhibit click here

About DAVIDsTEA Inc. (NASDAQ:DTEA)

DAVIDsTEA Inc. is engaged in the retail and online sale of tea, tea accessories, and food and beverages in Canada and in the United States. The Company’s segments include Canada and the U.S. The Company is a branded retailer of specialty tea, offering approximately 150 loose-leaf teas, pre-packaged teas, tea sachets and tea-related gifts, accessories, and food and beverages primarily through approximately 190 DAVIDsTEA stores, which are operated by the Company, and its Website, davidstea.com. Additionally, the Company offers on-the-go tea beverages in its retail stores. The Company’s tea accessories include tea mugs, travel mugs, teacup sets, teapots, tea makers, kettles, infusers, filters, frothers, tins and spoons. The Company offers beverages range from the standard hot or iced tea to its Tea Lattes. The Company’s different flavors of loose-leaf tea span eight tea categories: white, green, oolong, black, pu’erh, mate, rooibos and herbal tea.

Story continues below

BIO-key International, Inc. (OTCMKTS:BKYID) Files An 8-K Submission of Matters to a Vote of Security Holders

BIO-key International, Inc. (OTCMKTS:BKYID) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07      Submission of Matters to a Vote of Security Holders.

About BIO-key International, Inc. (OTCMKTS:BKYID)

BIO-key International, Inc. develops and markets fingerprint biometric identification and identity verification technologies, cryptographic authentication-transaction security technologies, as well as related identity management and credentialing software solutions. The Company is also engaged in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, identity cards, public key infrastructure (PKI), credit card, passports, driver’s licenses, one-time password (OTP) or other form of possession or knowledge-based credentialing. Its solutions identify individuals and verify, or confirm, their identity before granting access to, among other things, corporate resources, subscribed data and services, Web portals, applications, physical locations or assets.

Story continues below

MANNATECH, INCORPORATED (NASDAQ:MTEX) Files An 8-K Submission of Matters to a Vote of Security Holders

MANNATECH, INCORPORATED (NASDAQ:MTEX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders

Mannatech, Incorporated (the “Company”) held its 2021 Annual Shareholders’ Meeting (the "Meeting") on June 15, 2021. The Company’s shareholders considered three proposals, each of which is described in the Proxy Statement. A total of 1,450,658 shares were represented in person or by proxy at the Meeting, or approximately 70.3% of the total shares outstanding. The final results of votes with respect to the proposals submitted for shareholder vote at the Meeting are set forth below.
Proposal 1 – Election of Directors
Shareholders elected Larry A. Jobe and Kevin Robbins as Class I directors.
Proposal 2 – Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
Shareholders ratified the appointment of BDO USA, LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2021.
*Furnished herewith.
MANNATECH INC Exhibit
EX-99.1 2 mtexexh9912021shareholderm.htm EX-99.1 DocumentExhibit 99.1CONTACTDonna Giordano972-471-6512ir@mannatech.comMannatech Announces Results of Annual Shareholders’ MeetingFLOWER MOUND,…
To view the full exhibit click here

About MANNATECH, INCORPORATED (NASDAQ:MTEX)

Mannatech, Incorporated is a wellness solution provider. The Company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products. The Company operates through the segment of sale of nutritional supplements, skin care and anti-aging products, and weight management and fitness products through network marketing distribution channels in approximately 20 countries. Its Health category includes a range of daily nutritional supplements, health solutions for children and additional nutrients designed to help keep specific body systems at optimal levels. Its Weight and Fitness category offers products designed to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion. Its Skin Care and Anti-Aging category offers products formulated with approximately 30 botanical ingredients. It sells products in three regions: North America/South America, Europe/the Middle East/Africa (EMEA) and Asia/Pacific.

Story continues below

FUSE SCIENCE, INC. (OTCMKTS:DROP) Files An 8-K Other Events

FUSE SCIENCE, INC. (OTCMKTS:DROP) Files An 8-K Other Events
Item 8.01 – Other Events

The company is pleased to announce the company coming as part of DROP has changed the name from jumbbble to kustomeroo. We feel the new name is more inline with our mission of transforming how people think about customer service. David Delke founder of kustomeroo will work to keep everyone updated via formal channels as well as Twitter @daviddelke, @kustomeroo and https://kustomeroo.com . The company will have an investor and shareholder event on its Twitch channel https://www.twitch.tv/kustomeroo on Wednesday, July 21st at 6pm (EST) to discuss current and future partnerships along with product roadmap and long term vision of the company.

The management is of the opinion that this is a material event and as a voluntary SEC filer is making the market aware of its activities. The management is applying to OTC Markets to gain access to OTCIQ in order to file its periodic filings and get the company current.

The company has no existing debt.

The Company intends to do a name change in concert with its new business. The management does not anticipate disturbing the share structure with any sort of a share stock split.


About FUSE SCIENCE, INC. (OTCMKTS:DROP)

Fuse Science, Inc., through its subsidiary, Spiral Energy Tech, Inc. (Spiral), is focused on developing and commercializing its SkyPorts drone support and Energy Demand Network (EDEN) technology. The Company, through Spiral, is also engaged in developing and commercializing its XTRAX remote monitoring system, which is designed to measure the production of solar and other renewable energy systems and to enable transmission of the data through the cellular and radio frequency network (and through microwave transmission network or satellite). As of June 30, 2015, the Company had not generated any revenues. The Company was engaged in developing and marketing nutraceutical products.

Story continues below

SEQUENTIAL BRANDS GROUP, INC. (NASDAQ:SQBG) Files An 8-K Entry into a Material Definitive Agreement

SEQUENTIAL BRANDS GROUP, INC. (NASDAQ:SQBG) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On June 17, 2021, Sequential Brands Group, Inc. (“Sequential” or the “Company”) entered into a waiver (the “Waiver”) under its Third Amended and Restated First Lien Credit Agreement, dated as of July 1, 2016 (as amended, restated or otherwise modified from time to time, the “Amended BOA Credit Agreement”), with Bank of America, N.A. (“BoA”), as administrative agent and collateral agent, and the lenders party thereto.  The Waiver, among other matters, waives any and all existing defaults and/or events of default related to the Company’s (i) failure to deliver quarterly financial statements for the period ended March 31, 2021 (the “Quarterly Financial Statements”), (ii) failure to deliver a quarterly compliance certificate for the period ended March 31, 2021(the “Quarterly Compliance Certificate”) and (iii) failure to comply with the Loan to Value Ratio Covenant based on the most recent appraisal conducted on behalf of BoA and received by the Company on June 11, 2021, in each case, until June 24, 2021. The Company and BoA are negotiating terms and conditions of an additional waiver related to the events of default. BoA and the required lenders had previously waived events of default under the Amended BOA Credit Agreement related to the Company’s failure to deliver the Quarterly Financial Statements and the Quarterly Compliance Certificate until June 8, 2021, which such waiver was subsequently extended until June 15, 2021. Wilmington Trust, National Association and the required lenders had previously waived events of default under the Third Amended and Restated Credit Agreement, dated as of July 1, 2016, among the Company, certain subsidiaries of the Company party thereto, Wilmington Trust, National Association, as administrative agent and collateral agent, and the lenders party thereto, related to the Company’s failure to deliver the Quarterly Financial Statements and the Quarterly Compliance Certificate until June 8, 2021, which such waiver was subsequently extended until June 21, and thereafter until July 8, 2021. The Waiver is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description
 
10.1 Waiver to Amended BOA Credit Agreement, dated as of June 17, 2021, between Sequential Brands Group, Inc., Bank of America, N.A., as administrative agent and collateral agent, and the lenders party thereto.
 


Sequential Brands Group, Inc. Exhibit
EX-10.1 2 tm2120060d1_ex10-1.htm EXHIBIT 10.1   Exhibit 10.1   June 17,…
To view the full exhibit click here

About SEQUENTIAL BRANDS GROUP, INC. (NASDAQ:SQBG)

Sequential Brands Group, Inc. owns a portfolio of consumer brands in the fashion, home, athletic and lifestyle categories. The Company’s portfolio of consumer brands includes Martha Stewart, Emeril Lagasse, Jessica Simpson, Joe’s Jeans, William Rast, Ellen Tracy, Revo, AND1 and Avia. The Company’s brands are licensed for a range of product categories, including apparel, footwear, eyewear, fashion accessories and home goods. The Company licenses brands to both wholesale and direct-to-retail licensees. The Company licenses the Martha Stewart brand to various licensees, including retailers, such as Macy’s, The Home Depot, PetSmart and Staples. The Jessica Simpson Collection is a signature lifestyle concept designed in collaboration with Jessica Simpson, which offers various product categories, including footwear, apparel, fragrance, fashion accessories, maternity apparel, girls clothing and a home line. The Avia brand offers running and activewear products.

Story continues below